Curaleaf Raises Aurora Cannabis Offer 25% to US$5 a Share

Curaleaf lifts the bid to US$5 a share

Curaleaf (CSE: CURA) raised its takeover offer for Aurora Cannabis (TSX: ACB) by 25% on Oct. 5, setting total implied consideration at US$5 per Aurora share.

According to Cannabis Business Times, the new price is an 86% premium to Aurora's unaffected share price. That qualifier matters. "Unaffected" means the price before the bid moved the stock, and it's the yardstick boards and shareholders use to judge whether an offer is fair.

Curaleaf didn't bring a new deal. It sweetened an existing one. A raised bid means the first version didn't close the gap, at least in Curaleaf's judgment.

The phrase "total implied consideration" deserves a second look. It leaves open that part of the value floats, depending on how the package is built and measured. The report didn't break out the mix, and that's the detail to chase.

The per-share math points to a prior bid near US$4

Working backward from the reported figures, the earlier offer was roughly US$4.00 per share and Aurora's unaffected price was roughly US$2.69.

These are CannIntel calculations, not disclosed numbers. A 25% increase that lands at US$5 implies a prior price of US$4.00, and an 86% premium at US$5 implies a reference price near US$2.69.

• Increase: about US$1.00 per share over the implied prior bid.
• Prior premium: roughly 49% to the implied unaffected price.
• New premium: 86%, per Cannabis Business Times.

That's a 37-point jump in premium in one revision. Buyers don't add that much unless they expect resistance, or a rival, or both.

For an acquirer, a premium that size has to be underwritten by synergies. Curaleaf would need to show the combined company covers the extra dollar per share through cost savings or higher EBITDA, and because neither company's modeling appears in the signal, that case remains unverified.

Premiums this large also tell you something about how the target is valued in the public market. Cannabis equities have traded at steep discounts to revenue for years, and a bid that nearly doubles the pre-bid price is a statement about that gap. That math is hard to ignore.

What Aurora holders still need to see

The report doesn't say whether Aurora's board supports the revised offer, what form the consideration takes, or when shareholders would vote.

Those gaps decide whether US$5 is a headline or a deal. Four items will carry the most weight in any follow-up filing or circular:

1. The cash-versus-stock split and how the "implied" value was calculated.
2. The Aurora board's formal recommendation.
3. Conditions, including financing and shareholder approval thresholds.
4. Regulatory clearances, including Canadian review.

The cross-border structure adds friction. Aurora is a Canadian licensed producer, while Curaleaf is a U.S. multistate operator whose business still sits in a different federal legal position. Any combination has to reconcile Health Canada oversight with U.S. tax treatment such as 280E, which hits plant-touching U.S. operators. The signal doesn't address how the parties plan to handle either point.

Not yet. That's the honest status of the answer.

For full background on this story, see the CannIntel topic hub on the Curaleaf-Aurora Cannabis takeover bid.

The next signal: Aurora's formal response to the US$5 offer, and whether the filing spells out the cash-versus-stock mix. If a competing bidder surfaces before then, the premium math changes again.